WO2002026708A1 - Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif - Google Patents

Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif Download PDF

Info

Publication number
WO2002026708A1
WO2002026708A1 PCT/JP2001/008466 JP0108466W WO0226708A1 WO 2002026708 A1 WO2002026708 A1 WO 2002026708A1 JP 0108466 W JP0108466 W JP 0108466W WO 0226708 A1 WO0226708 A1 WO 0226708A1
Authority
WO
WIPO (PCT)
Prior art keywords
nitrogen
active ingredient
same
containing compounds
ccr3 inhibitors
Prior art date
Application number
PCT/JP2001/008466
Other languages
English (en)
Japanese (ja)
Inventor
Toshiya Takahashi
Takayuki Imaoka
Hiroki Tomioka
Daigo Hatakeyama
Aiko Nitta
Masayuki Kaneko
Satoko Takizawa
Yuichi Torii
Koichiro Morihira
Tatsuaki Morokata
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Priority to AU2001292276A priority Critical patent/AU2001292276A1/en
Publication of WO2002026708A1 publication Critical patent/WO2002026708A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés contenant de l'azote, représentés par la formule générale (I), utiles en tant qu'inhibiteurs de CCR3, dans la prévention et le traitement de maladies inflammatoires allergiques provoquées par la leukergie des lymphocytes, éosinocytes, leukocytes basophiles, et analogue; elle concerne également des sels de ces composés, acceptables sur le plan pharmacologique. Dans la formule (I), l représente un nombre entier compris entre 0 et 2, m représente un nombre entier compris entre 0 et 5, Ar représente aryle, tel que 2-1,2,3,4-tétrahydro-isoquinolyle, phényle ou pyridyle, A représente un groupe divalent contenant de l'azote, tel que -CONH-, et B représente, par exemple, 4-(diphénylméthyl)pipéridino.
PCT/JP2001/008466 2000-09-27 2001-09-27 Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif WO2002026708A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292276A AU2001292276A1 (en) 2000-09-27 2001-09-27 Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000-294355 2000-09-27
JP2000294355 2000-09-27
JP2000-313405 2000-10-13
JP2000313405 2000-10-13

Publications (1)

Publication Number Publication Date
WO2002026708A1 true WO2002026708A1 (fr) 2002-04-04

Family

ID=26600853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008466 WO2002026708A1 (fr) 2000-09-27 2001-09-27 Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif

Country Status (2)

Country Link
AU (1) AU2001292276A1 (fr)
WO (1) WO2002026708A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076448A1 (fr) * 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag Antagonistes du recepteur ccr-3
WO2005040129A2 (fr) * 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag Antagonistes du recepteur ccr3
WO2008123582A1 (fr) 2007-04-04 2008-10-16 Kowa Company, Ltd. Composé de tétrahydroisoquinoline
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516714A (fr) * 1962-11-07 1968-02-05 Bayer Ag Procédé de préparation de dérivés de l'imidazolidine
WO1992014697A1 (fr) * 1991-02-08 1992-09-03 Cambridge Neuroscience, Inc. Guanidines substituees et leurs derives utilises comme modulateurs de liberation de neurotransmetteurs et nouveau procede d'identification d'inhibiteurs de liberation de neurotransmetteurs
US5780474A (en) * 1996-06-04 1998-07-14 Adir Et Compagnie 3-(piperid-4-yl)-1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds
WO2000035449A1 (fr) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516714A (fr) * 1962-11-07 1968-02-05 Bayer Ag Procédé de préparation de dérivés de l'imidazolidine
WO1992014697A1 (fr) * 1991-02-08 1992-09-03 Cambridge Neuroscience, Inc. Guanidines substituees et leurs derives utilises comme modulateurs de liberation de neurotransmetteurs et nouveau procede d'identification d'inhibiteurs de liberation de neurotransmetteurs
US5780474A (en) * 1996-06-04 1998-07-14 Adir Et Compagnie 3-(piperid-4-yl)-1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds
WO2000035449A1 (fr) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081531B2 (en) 2003-02-27 2006-07-25 Roche Palo Alto Llc Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists
WO2004076448A1 (fr) * 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag Antagonistes du recepteur ccr-3
WO2005040129A2 (fr) * 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag Antagonistes du recepteur ccr3
WO2005040129A3 (fr) * 2003-10-24 2005-06-23 Hoffmann La Roche Antagonistes du recepteur ccr3
JP2007509095A (ja) * 2003-10-24 2007-04-12 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｃｒ３受容体アンタゴニスト
WO2008123582A1 (fr) 2007-04-04 2008-10-16 Kowa Company, Ltd. Composé de tétrahydroisoquinoline
US8273766B2 (en) 2007-04-04 2012-09-25 Kowa Company, Ltd. Tetrahydroisoquinoline compound
JP5313881B2 (ja) * 2007-04-04 2013-10-09 興和株式会社 テトラヒドロイソキノリン化合物
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11987580B2 (en) 2017-01-11 2024-05-21 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Also Published As

Publication number Publication date
AU2001292276A1 (en) 2002-04-08

Similar Documents

Publication Publication Date Title
DK0664126T3 (da) Hæmning af trombin
WO2001072728A3 (fr) Nouveaux derives de piperazine
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
ATE234094T1 (de) 2-phenyl-3-aroylbenzothiophene zur behandlung der menstruellen symptome
WO1994022835A3 (fr) Composes heterocycliques en tant qu'inhibiteurs de l'agregation plaquettaire
NO990667L (no) Depeptid-benzamidin som kinogenase-inhibitor
CA2424522A1 (fr) Derives de benzene substitues ou leurs sels
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
CA2040947A1 (fr) Inhibiteurs de l'agregation des plaquettes
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
DE69412049T2 (de) Hemmung von dysfunctionalen Uterusblutungen
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
WO2002026708A1 (fr) Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif
EP0277725A3 (fr) 4-Aryl-N-[2-(dialcoylamino et hétérocyclicamino)alcoyl]-1-pipérazinecarboxamides et leur utilisation comme agents anti-allergiques
EP0309425A3 (fr) Dérivés hétérocycliques
ES2191763T3 (es) Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.
CA2118425A1 (fr) Derive du benzothiazolesulfamide, son mode de preparation et son utilisation
DE69226931D1 (de) Guanidinothiazolederivate und ihre Anwendung als H2-Rezeptor-Antagonisten
CA2025490A1 (fr) Alkyl piperidines subtituees et leur utilisation comme inhibiteurs de la synthese du cholesterol
EP1505067A4 (fr) Derives de piperidine 4,4 disubstitues a antagonisme pour ccr3
EP1076056A4 (fr) Nouveaux composes spiro et sels de ceux-ci, prophylaxie et medicaments contre des maladies auto-immunes et inhibiteurs de ap-1 contenant lesdits composes
ATE93522T1 (de) Thioformamidderivate.
WO2003042188A1 (fr) Derive de triazole, et composition medicamenteuse renfermant ce derive
CA2416706A1 (fr) Medicaments contre la demence contenant des derives de 2-aryl-8-oxodihydropurine comme ingredient actif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase